ClinicalTrials.gg
CompletedNCT00143325Updated Jun 4, 2007

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

A Phase 3 interventional study of varenicline (CP-526,555) in Smoking Cessation, sponsored by Pfizer. Completed at 24 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2007-06-04.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
730
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing varenicline in Smoking Cessation — 5 open to participants now, 7 under way, 2 of them phase 3. Varenicline · Smoking Cessation.

Enrollment
13th of 110
730 · median 209
Started
2005
with 2 others
Phase 3
24 of 110
1 open now
Registered
4th of 110
by date
Lead sponsor
26 of 110
Pfizer

Among the 110 studies testing varenicline in Smoking Cessation, this one is the 13th largest by enrollment, is one of 3 that started in 2005, is one of 24 in phase 3, and was the 4th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

5 of the 110 studies testing varenicline in Smoking Cessation are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing varenicline in Smoking Cessation, or all of them as a file.
02

Study summary

Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.

03

Conditions studied

  • Smoking Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion criteria

Exclusion Criteria:

  • Subjects with cardiovascular disease in the past 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
730 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Continuous abstinence for the last 4 weeks of varenicline and NRT (Nicotine Replacement Therapy) treatment period

Secondary outcomes

  1. Continuous abstinence last 4 weeks of treatment through Weeks 24 and 52

  2. 7-day point prevalence of abstinence: end of treatment, Weeks 24 and 52

  3. 4-week Point Prevalence of abstinence at Week 52

  4. Long-Term Quit Rate at Weeks 24 and 52

  5. Minnesota Nicotine Withdrawal Scale

  6. Smoking Effects Inventory

07

Study locations

24 sites
  • Pfizer Investigational Site
    Palo Alto, California, United States
  • Pfizer Investigational Site
    Santa Ana, California, United States
  • Pfizer Investigational Site
    Farmington, Connecticut, United States
  • Pfizer Investigational Site
    Lexington, Kentucky, United States
  • Pfizer Investigational Site
    Worcester, Massachusetts, United States
  • Pfizer Investigational Site
    Portland, Oregon, United States
  • Pfizer Investigational Site
    Bruxelles, Belgium
  • Pfizer Investigational Site
    Edegem, Belgium
  • Pfizer Investigational Site
    Gent, Belgium
  • Pfizer Investigational Site
    Caen, France
  • Pfizer Investigational Site
    Clermont-Ferrand, France
  • Pfizer Investigational Site
    Limeil Brevannes, France
  • Pfizer Investigational Site
    Limeil-Brevannes, France
  • Pfizer Investigational Site
    Metz CEDEX 01, France
  • Pfizer Investigational Site
    Metz Cedex 1, France
  • Pfizer Investigational Site
    Paris, France
  • Pfizer Investigational Site
    Vandoeuvre les Nancy, France
  • Pfizer Investigational Site
    Amsterdam, Netherlands
  • Pfizer Investigational Site
    Enschede, Netherlands
  • Pfizer Investigational Site
    Maastricht, Netherlands
  • Pfizer Investigational Site
    Zutphen, Netherlands
  • Pfizer Investigational Site
    London, Surrey, United Kingdom
  • Pfizer Investigational Site
    London, United Kingdom
  • Pfizer Investigational Site
    Nottingham, United Kingdom
08

References and documents

Publications

  • Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, Williams KE, Reeves KR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug;63(8):717-24. doi: 10.1136/thx.2007.090647. Epub 2008 Feb 8. PubMed 18263663 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005 and a completion of Jun 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 2, 2005
Start
Jan 2005
CompletionActual
Jun 2006
Last update
Jun 4, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00143325
Lead sponsor
Pfizer
First posted
Sep 2, 2005
Start date
Jan 2005
Completion
Jun 2006
Last update
Jun 4, 2007

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion